SUNNYVALE, Calif., April 12, 2017 /PRNewswire/
-- Renowned radiation oncologists, physicists, therapists
and administrators from around the world joined together at the
Accuray Exchange in Radiation Oncology (AERO™) Users' Summit to
discuss best practices and further collaborations that will improve
cancer patients' outcomes and quality of life. The Accuray
Incorporated (NASDAQ: ARAY) summit was held April 7 – 8, 2017 at the Hyatt Chicago
Magnificent Mile Hotel in Chicago,
Illinois.
"The Accuray AERO Users' Summits were established in response to
customers' requests for additional peer-to-peer learning
opportunities. Our customers have told us that this type of meeting
provides them with an invaluable opportunity to share best
practices and learn about innovative approaches to improving
treatment results for their patients," said Fabienne
Hirigoyenberry-Lanson, PhD, Vice President Global Medical and
Scientific Affairs, at Accuray.
More than two dozen of the radiation oncology industry's leading
clinicians shared information on how to optimize treatment results
using the Accuray CyberKnife®, TomoTherapy® and Radixact™ Systems,
and PreciseART™ Adaptive Radiation Therapy option. Meeting
participants were able to engage in conversations on topics ranging
from prostate cancer and nasopharyngeal cancer outcomes, to Iris™
Collimator versus InCise™ Multileaf Collimator in the treatment of
liver cancer, and Radixact customer treatment experiences.
Additional meeting highlights included:
- Special sessions on the Accuray state of the business and
product roadmap
- A keynote address on "The Future of the Affordable Care Act and
our U.S. Healthcare Environment"
- Breakout sessions specially created for Administrators and
Radiation Therapists
Said Kelly Londy, Executive Vice
President, Chief Operating Officer at Accuray, "This summit
provided our team with the opportunity to be a part of a unique
radiation therapy think tank comprised of some of the most
knowledgeable and experienced clinicians in the world. We came
together to advance common goals – improving the standard of care
for cancer patients and the way radiation therapy is
delivered."
About AERO
Founded in 2011, AERO was created for CyberKnife System and
TomoTherapy System users dedicated to advancing patient care
through worldwide clinical and technical partnerships. The AERO
community mission is to provide a global forum for the clinical
exchange of information between clinicians and physicists for the
purpose of setting a new standard in patient care and safety across
treatments in the fields of SRS/SBRT, IMRT and conventional
radiation therapy. Membership to AERO is free and open to all users
of the CyberKnife, TomoTherapy and Radixact Systems.
Accuray is pleased to sponsor the 2017 Accuray pre-ESTRO
Planning Workshop for all AERO™ members, to be held at the Hotel
Melia in Vienna, Austria on
Friday, May 5, 2017, from
12:00pm to 5:00pm. To learn more,
visit www.accurayexchange.com.
About the CyberKnife®, TomoTherapy® and Radixact™ Systems
The Accuray CyberKnife M6™ Series, TomoTherapy H™ Series and
Radixact treatment solutions cover the entire spectrum of radiation
therapy needs. The CyberKnife M6 Series enables precise,
high-quality, dose distributions to be confidently delivered to the
patient with extreme accuracy over a minimum number of treatments,
reducing side effects and preserving patients' quality of life. The
CyberKnife System is the only robotic full-body radiosurgery system
available today. The TomoTherapy H Series efficiently enables
physicians to customize treatment plans for the entire range of
radiation therapy patients and disease types. Its innovative design
enables treatment plans to be delivered with integrated, daily CT
image guidance, enhancing accuracy and delivering highly precise,
intensity-modulated radiation for optimal sparing of healthy tissue
and critical structures. The Radixact System empowers clinicians by
integrating treatment planning, data management and treatment
delivery. Using low-dose fan beam megavoltage x-ray radiation,
refined beamline and fast imaging technology, the system delivers
scalable and highly reliable treatment for patients with a variety
of treatment requirements.
Further information on Accuray and the CyberKnife, TomoTherapy
and Radixact Systems is available at www.accuray.com.
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement-radiation-treatment.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes and Accuray's leadership
position in radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed from
time to time under the heading "Risk Factors" in the company's
report on Form 10-K, filed on August 24,
2016, the company's reports on Form 10-Q, filed on
November 1, 2016 and February 3, 2017, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jane Hauser
MSLGROUP
+1 (781) 684-0770
accuray@mslgroup.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/accuray-2017-regional-aero-summit-brings-together-leading-oncology-specialists-to-advance-cancer-patient-care-300438442.html
SOURCE Accuray Incorporated